COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,440 Articles (22,835 medRxiv, 8,605 bioRxiv)

Most recent first Previous |  Page 1949: Articles 19481-19490  | Next

Primary care during the COVID-19 pandemic - observations and challenges identified through a survey and interviews with community paediatricians: the calm before the storm
Kohns Vasconcelos, M., Weil, K., Vesterling-Hoerner, D., Klemm, M., el Scheich, T., Renk, H., Remke, K., Bosse, H. M.
10.1101/2020.12.30.20249037 — Posted: 2021-01-04
SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage
Grabowski, F., Preibisch, G., Kochanczyk, M., Lipniacki, T.
10.1101/2020.12.28.20248906 — Posted: 2021-01-04
COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and may be modified by dexamethasone
Sarma, A., Christenson, S. A., Mick, E., DeVoe, C., Deiss, T., Pisco, A. O., Ghale, R., Jauregui, A., Byrne, A., Moazed, F., Spottiswoode, N., Sinha, P., Zha, B. S., Serpa, P. H., Ansel, K. M., Wilson, J. G., Leligdowicz, A., Siegel, E. R., Sirota, M., DeRisi, J. L., Matthay, M. A., COMET Consortium, , Hendrickson, C. M., Kangelaris, K. N., Krummel, M., Woodruff, P. G., Erle, D. J., Calfee, C. S., Langelier, C. R.
10.1101/2020.12.28.20248552 — Posted: 2021-01-04
COVID-19 vaccine hesitancy worldwide: a systematic review of vaccine acceptance rates
Sallam, M.
10.1101/2020.12.28.20248950 — Posted: 2021-01-04 Discussion: Onsite
Autoimmunity to the Lung Protective Phospholipid-Binding Protein Annexin A2 Predicts Mortality Among Hospitalized COVID-19 Patients
Zuniga, M., Gomes, C., Carsons, S. E., Bender, M. T., Cotzia, P., Miao, Q. R., Lee, D. C., Rodriguez, A.
10.1101/2020.12.28.20248807 — Posted: 2021-01-04
Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase
Mari, A., Roloff, T.-C., Stange, M., Soegaard, K. K., Asllanaj, E., Tauriello, G., Alexander, L. T., Schweitzer, M., Leuzinger, K., Gensch, A., Martinez, A., Bielicki, J., Pargger, H., Siegemund, M., Nickel, C., Bingisser, R., Osthoff, M., Bassetti, S., Sendi, P., Battegay, M., Marzolini, C., Seth-Smith, H., Schwede, T., Hirsch, H. H., Egli, A.
10.1101/2020.12.28.20248663 — Posted: 2021-01-04
Postlockdown Dynamics of COVID-19 in New York, Florida, Arizona, and Wisconsin
Scott, S., Cook, K., Barley, K.
10.1101/2020.12.28.20248967 — Posted: 2021-01-04
COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review
LEPERE, P., Escarguel, B., Yolartiran, S., Escarguel, C.
10.1101/2020.12.29.20248975 — Posted: 2021-01-04
High levels of plasminogen activator inhibitor-1, tissue plasminogen activator and fibrinogen in patients with severe COVID-19
Cabrera-Garcia, D., Miltiades, A., Parsons, S. M., Elisman, K., Mansouri, M. T., Wagener, G., Harrison, N. L.
10.1101/2020.12.29.20248869 — Posted: 2021-01-04
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
Banach, B. B., Cerutti, G., Fahad, A. S., Shen, C.-H., Oliveira de Souza, M., Katsamba, P. S., Tsybovsky, Y., Wang, P., Nair, M. S., Huang, Y., Francino Urdaniz, I. M., Steiner, P. J., Gutierrez-Gonzalez, M., Liu, L., Lopez Acevedo, S. N., Nazzari, A., Wolfe, J. R., Luo, Y., Olia, A. S., Teng, I.-T., Yu, J., Zhou, T., Reddem, E. R., Bimela, J., Pan, X., Madan, B., Laflin, A. D., Nimrania, R., Yuen, K.-T., Whitehead, T. A., Ho, D. D., Kwong, P. D., Shapiro, L., DeKosky, B. J.
10.1101/2020.12.31.424987 — Posted: 2021-01-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).